{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Eyes+With+Retinal+Diseases&page=2",
    "query": {
      "condition": "Eyes With Retinal Diseases",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Eyes+With+Retinal+Diseases&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T08:15:16.801Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05532735",
      "title": "Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "ANXV",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Annexin Pharmaceuticals AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2022-08-24",
      "completion_date": "2024-11-11",
      "has_results": false,
      "last_update_posted_date": "2024-12-11",
      "last_synced_at": "2026-05-22T08:15:16.801Z",
      "location_count": 7,
      "location_summary": "West Monroe, Louisiana • Hagerstown, Maryland • Tulsa, Oklahoma + 4 more",
      "locations": [
        {
          "city": "West Monroe",
          "state": "Louisiana"
        },
        {
          "city": "Hagerstown",
          "state": "Maryland"
        },
        {
          "city": "Tulsa",
          "state": "Oklahoma"
        },
        {
          "city": "Bellaire",
          "state": "Texas"
        },
        {
          "city": "McAllen",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05532735"
    },
    {
      "nct_id": "NCT06132035",
      "title": "Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Age-related Wet Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "CG-P5 peptide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept Injection [Eylea]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Caregen Co. Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2023-12-22",
      "completion_date": "2025-08",
      "has_results": false,
      "last_update_posted_date": "2025-02-07",
      "last_synced_at": "2026-05-22T08:15:16.801Z",
      "location_count": 7,
      "location_summary": "Manchester, Connecticut • Deerfield Beach, Florida • Augusta, Georgia + 4 more",
      "locations": [
        {
          "city": "Manchester",
          "state": "Connecticut"
        },
        {
          "city": "Deerfield Beach",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Carmel",
          "state": "Indiana"
        },
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06132035"
    },
    {
      "nct_id": "NCT00438243",
      "title": "Pilot Study of the Effect of Topical Bromfenac Ophthalmic Solution 0.09%in Patients With Acute Post-operative Cystoid Macular Edema.",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cystoid Macular Edema"
      ],
      "interventions": [
        {
          "name": "Bromfenac (Xibrom)",
          "type": "DRUG"
        },
        {
          "name": "Refresh Plus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2008-05",
      "completion_date": "2010-09",
      "has_results": false,
      "last_update_posted_date": "2016-07-04",
      "last_synced_at": "2026-05-22T08:15:16.801Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00438243"
    },
    {
      "nct_id": "NCT06033703",
      "title": "Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Rhegmatogenous Retinal Detachment",
        "Proliferative Vitreoretinopathy"
      ],
      "interventions": [
        {
          "name": "Netarsudil Ophthalmic",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts Eye and Ear Infirmary",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2025-01-14",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-10-28",
      "last_synced_at": "2026-05-22T08:15:16.801Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06033703"
    },
    {
      "nct_id": "NCT05932069",
      "title": "Active AMD Study to Improve Function in Veterans",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Age Related Macular Degeneration (AMD)"
      ],
      "interventions": [
        {
          "name": "SPIN",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Non-aerobic, stretching/balance intervention Control",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "65 Years to 89 Years"
      },
      "enrollment_count": 70,
      "start_date": "2024-03-01",
      "completion_date": "2028-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-23",
      "last_synced_at": "2026-05-22T08:15:16.801Z",
      "location_count": 1,
      "location_summary": "Decatur, Georgia",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05932069"
    },
    {
      "nct_id": "NCT04795206",
      "title": "Natural Disease Progression in Participants With Choroideremia",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Choroideremia"
      ],
      "interventions": [
        {
          "name": "No Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 1178,
      "start_date": "2020-08-26",
      "completion_date": "2021-08-10",
      "has_results": false,
      "last_update_posted_date": "2021-09-08",
      "last_synced_at": "2026-05-22T08:15:16.801Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04795206"
    },
    {
      "nct_id": "NCT00426998",
      "title": "Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Choroidal Neovascularization",
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Verteporfin",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Retinal Consultants Medical Group",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2006-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2007-01-26",
      "last_synced_at": "2026-05-22T08:15:16.801Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00426998"
    },
    {
      "nct_id": "NCT00002321",
      "title": "A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cytomegalovirus Retinitis",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Aldesleukin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Chiron Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-05-22T08:15:16.801Z",
      "location_count": 1,
      "location_summary": "Toledo, Ohio",
      "locations": [
        {
          "city": "Toledo",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002321"
    },
    {
      "nct_id": "NCT01710332",
      "title": "The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Central Serous Chorioretinopathy"
      ],
      "interventions": [
        {
          "name": "Intravitreal Aflibercept Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wills Eye",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 12,
      "start_date": "2012-10",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2017-06-16",
      "last_synced_at": "2026-05-22T08:15:16.801Z",
      "location_count": 2,
      "location_summary": "Huntingdon Valley, Pennsylvania • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Huntingdon Valley",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01710332"
    },
    {
      "nct_id": "NCT07230834",
      "title": "Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Geographic Atrophy (GA)"
      ],
      "interventions": [
        {
          "name": "Pozelimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2026-01-19",
      "completion_date": "2028-07-03",
      "has_results": false,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-05-22T08:15:16.801Z",
      "location_count": 5,
      "location_summary": "Lakewood, Colorado • East Weymouth, Massachusetts • Austin, Texas + 2 more",
      "locations": [
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "East Weymouth",
          "state": "Massachusetts"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "The Woodlands",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07230834"
    }
  ]
}